Obesity complicated by hypertension
Conditions
Interventions
None listed
Sponsors
Kagawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with obesity who are scheduled to initiate treatment with GLP-1 receptor agonists or GLP-1/GIP receptor agonists 2. Patients complicated by hypertension (receiving antihypertensive medication or having outpatient blood pressure of 140/90 mmHg or higher) 3. Patients aged 18 years or older 4. Written informed consent for participation in this study
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women 2. Patients considered inappropriate for participation by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in flow-mediated dilation (FMD) from baseline to 52 weeks after initiation of pharmacological treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in coefficient of variation of R-R intervals (CVRR), ACTH, serum cortisol, body weight, BMI, HbA1c, lipid profile, liver function, renal function, and ABI/CAVI from baseline to 52 weeks after treatment initiation. Exploratory analyses will also be performed to evaluate associations between changes in FMD and changes in CVRR, ACTH, and serum cortisol. | — |
Countries
Japan
Contacts
Public ContactTakanobu Saheki
Kagawa University Hospital Department of Clinical Laboratory
Outcome results
None listed